Increased bone mass with pamidronate treatment in rheumatoid arthritis - Results of a three-year randomized, double-blind trial

被引:105
作者
Eggelmeijer, F
Papapoulos, SE
vanPaassen, HC
Dijkmans, BAC
Valkema, R
Westedt, ML
Landman, JO
Pauwels, EKJ
Breedveld, FC
机构
[1] UNIV LEIDEN HOSP,DEPT RHEUMATOL,2300 RC LEIDEN,NETHERLANDS
[2] ST FRANCISCUS HOSP,ROTTERDAM,NETHERLANDS
[3] BRONOVO HOSP,THE HAGUE,NETHERLANDS
来源
ARTHRITIS AND RHEUMATISM | 1996年 / 39卷 / 03期
关键词
D O I
10.1002/art.1780390307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Osteoporosis is a frequent complication of rheumatoid arthritis (RA). We therefore investigated the effect of oral pamidronate therapy as a specific bone-sparing agent in RA. Methods. The study design was a 3-year randomized, double-blind trial of 300 mg oral pamidronate/day compared with placebo in 105 RA patients. Bone mineral density (BMD) measured at 12-month intervals was the primary efficacy parameter. Results. In 3 years, lumbar spine and forearm BMD increased significantly in the pamidronate-treated group (by 8.4 +/- 6.9% [mean +/- SEM] [P < 0.0001] and 5.2 +/- 6.5% [P < 0.005], respectively), compared with nonsignificant changes in the placebo-treated patients (increase of 0.6 +/- 5.2% and decrease of 1.2 +/- 5.8%, respectively). Femoral neck BMD increased in the pamidronate-treated group (by 2.6 +/- 8.6%) and decreased significantly in the placebo-treated group (by 4.0 +/- 1.3% [P < 0.005]). The changes in BMD with time at all 3 measurement sites were significantly different between the treatment groups (P < 0.0001). Changes in radiographic signs of joint damage and in disease activity were similar in the 2 groups. Conclusion. The present study provides the first evidence that long-term treatment with an orally administered bisphosphonate overcomes bone loss and increases bone mass when compared with placebo. This finding may have significance with regard to the treatment of patients with RA.
引用
收藏
页码:396 / 402
页数:7
相关论文
共 35 条
  • [1] ADAMI S, 1993, OSTEOPOROSIS INT S3, V3, P21
  • [2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [3] STUDIES ON THE CHRONIC PHASE OF ADJUVANT ARTHRITIS - EFFECT OF SR-41319, A NEW DIPHOSPHONATE
    BARBIER, A
    BRELIERE, JC
    REMANDET, B
    RONCUCCI, R
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1986, 45 (01) : 67 - 74
  • [4] BEAT AM, 1991, J RHEUMATOL, V18, P804
  • [5] APD IN PAGETS-DISEASE OF BONE - ROLE OF THE MONONUCLEAR PHAGOCYTE SYSTEM
    BIJVOET, OLM
    FRIJLINK, WB
    JIE, K
    VANDERLINDEN, H
    MEIJER, CJLM
    MULDER, H
    VANPAASSEN, HC
    REITSMA, PH
    TEVELDE, J
    DEVRIES, E
    VANDERWEY, JP
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (10): : 1193 - 1204
  • [6] BIJVOET OLM, 1989, CLIN DISORDERS BONE
  • [7] EGGELMEIJER F, 1993, CLIN EXP RHEUMATOL, V11, P381
  • [8] EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
  • [9] EGGELMEIJER F, 1993, BRIT J RHEUMATOL, V32, P387
  • [10] BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE
    FLEISCH, H
    [J]. DRUGS, 1991, 42 (06) : 919 - 944